Patents by Inventor Lin Zhi

Lin Zhi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11566041
    Abstract: Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: January 31, 2023
    Assignee: LIGAND PHARMACEUTICALS, INC.
    Inventor: Lin Zhi
  • Publication number: 20220336230
    Abstract: An interposer, which is used to connect two circuit boards, includes an inner structure (10), an outer structure (20), and a protective layer (50). The inner structure (10) includes a first base layer (11) and a first wiring layer (131) formed on the first base layer (11). The outer structure (20) includes a second base layer (21) and a second wiring layer (231) formed on the second base layer (21). An end portion of at least wiring line of the first wiring layer (131) and the second wiring layer (231) extends to a sidewall of the interposer (100). An end of another wiring line extends to the other sidewall of the interposer (100). The first wiring layer (131) is electrically connected to the second wiring layer (231) by a conductive blind hole (41).
    Type: Application
    Filed: September 27, 2019
    Publication date: October 20, 2022
    Inventors: MAN-ZHI PENG, RUI-WU LIU, SI XIONG, LIN-JIE GAO
  • Publication number: 20220298198
    Abstract: Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 22, 2022
    Inventor: Lin Zhi
  • Publication number: 20220298199
    Abstract: Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
    Type: Application
    Filed: July 15, 2020
    Publication date: September 22, 2022
    Inventor: Lin Zhi
  • Patent number: 11427550
    Abstract: The compounds are of the class of 5-fluorouracil derived acetal and hemiaminal ether compounds, useful in treating liver diseases and various types of cancer.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: August 30, 2022
    Assignee: NUCORION PHARMACEUTICALS, INC.
    Inventor: Lin Zhi
  • Patent number: 11413274
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 16, 2022
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelis Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Publication number: 20220220145
    Abstract: Provided herein are cyclic phosphate compounds, their preparation and their uses, such as treating liver diseases or conditions or a disease or condition in which the physiological or pathogenic pathways involve the liver.
    Type: Application
    Filed: April 21, 2020
    Publication date: July 14, 2022
    Inventor: Lin Zhi
  • Publication number: 20220204448
    Abstract: Disclosed herein are methods of crystallizing the compound of Formula (I), as well as crystalline forms thereof. Crystalline forms of Formula (I) disclosed include crystalline Form C, crystalline Form E, and Crystalline form B.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 30, 2022
    Inventors: Lin Zhi, Henri Sasmor
  • Publication number: 20220205736
    Abstract: The present application discloses a microchannel flat tube and a microchannel heat exchanger. The microchannel flat tube includes a flat tube body and a row of channels. The row of channels is arranged in the flat tube body along a width direction. The row of channels extends through the flat tube body along a length direction. A cross-section of each channel includes a first width in the width direction and a first height in a thickness direction. The row of channels at least includes a first group of first channels, a second group of second channels and a third group of third channels along the width direction. The first widths of the first channels, the second channels and the third channels decrease at a fixed rate, thereby facilitating the control of the thickness of the microchannel flat tube and improving the heat exchange efficiency of the third channels.
    Type: Application
    Filed: March 20, 2022
    Publication date: June 30, 2022
    Inventors: HAOBO JIANG, LI-ZHI WANG, JIAN-LONG JIANG, LIN-JIE HUANG
  • Patent number: 11358931
    Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: June 14, 2022
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Publication number: 20220119413
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Application
    Filed: October 28, 2021
    Publication date: April 21, 2022
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 11278559
    Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 22, 2022
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 11186593
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: November 30, 2021
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Publication number: 20210188887
    Abstract: Provided herein are phosphor(n)amidatacetal and phosph(on)atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver.
    Type: Application
    Filed: January 8, 2019
    Publication date: June 24, 2021
    Inventor: Lin Zhi
  • Publication number: 20210121422
    Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.
    Type: Application
    Filed: February 13, 2019
    Publication date: April 29, 2021
    Inventors: Lin Zhi, Ian Henderson, Joseph Kaloko, Martin Osterhout
  • Publication number: 20210046045
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 18, 2021
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelis Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Publication number: 20210040102
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 11, 2021
    Inventor: Lin Zhi
  • Patent number: 10874638
    Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: December 29, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Publication number: 20200399227
    Abstract: Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
    Type: Application
    Filed: July 15, 2020
    Publication date: December 24, 2020
    Inventor: Lin Zhi
  • Publication number: 20200361866
    Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Inventor: Lin Zhi